

Lifetime Probability of Developing and Dying from Cancer, 2012-2014

	MALES				FEMALES			
	Developing		Dying		Developing		Dying	
	%	1 in...	%	1 in...	%	1 in...	%	1 in...
All Sites*	39.7	3	22.0	5	37.6	3	18.8	5
Brain & ONS	0.7	143	0.5	190	0.5	184	0.4	242
Breast	0.1	805	<0.1	3,184	12.4	8	2.6	38
Colorectal	4.5	22	1.9	52	4.2	24	1.7	58
Esophagus	0.8	131	0.8	130	0.2	452	0.2	494
Hodgkin lymphoma	0.2	435	<0.1	2,506	0.2	539	<0.1	3,395
Kidney & renal pelvis	2.1	48	0.6	163	1.2	83	0.3	299
Larynx	0.5	183	0.2	507	0.1	805	<0.1	2,178
Leukemia	1.8	56	1.0	98	1.3	80	0.7	141
Liver & intrahepatic bile duct	1.4	72	1.0	101	0.6	166	0.5	194
Lung & bronchus	6.9	15	6.0	17	5.9	17	4.7	21
Melanoma of skin†	3.6	27	0.5	192	2.4	42	0.3	396
Myeloma	0.9	113	0.5	209	0.6	154	0.4	257
Non-Hodgkin lymphoma	2.4	42	0.8	119	1.9	54	0.7	151
Oral cavity & pharynx	1.6	62	0.4	247	0.7	146	0.2	559
Ovary	--	--	--	--	1.3	78	0.9	108
Pancreas	1.6	63	1.4	72	1.5	65	1.3	74
Prostate	11.6	9	2.4	41	--	--	--	--
Stomach	1.0	95	0.5	215	0.7	153	0.3	322
Testis	0.4	252	<0.1	5,094	--	--	--	--
Thyroid	0.6	160	<0.1	1,791	1.8	56	<0.1	1,442
Urinary bladder‡	3.8	27	0.9	107	1.1	89	0.3	293
Uterine cervix	--	--	--	--	0.6	162	0.2	445
Uterine corpus	--	--	--	--	2.8	35	0.6	166

*All sites excludes basal cell and squamous cell skin cancers and in situ cancers except urinary bladder.

†Statistics are for non-Hispanic whites.

‡Includes invasive and in situ cancer cases.

Source: Software: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.5, National Cancer Institute, 2017.